Odyssey Therapeutics, Inc. Common Stock (ODTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Odyssey Therapeutics, Inc. Common Stock (ODTX) has a cash flow conversion efficiency ratio of -0.082x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-34.51 Million) by net assets ($421.22 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ODTX market cap for the company's overall valuation and market capitalisation.
Odyssey Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Odyssey Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Odyssey Therapeutics, Inc. Common Stock for real-time trading data and today's change.
Odyssey Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Odyssey Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency. Review financial agility of Odyssey Therapeutics, Inc. Common Stock to assess the company's free cash flow relative to its total liabilities.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
KBC Corporation Ltd
SHG:688598
|
-0.008x |
|
Plazza AG
SW:PLAN
|
0.016x |
|
Creades AB
ST:CRED-A
|
-0.001x |
|
Southside Bancshares, Inc.
NASDAQ:SBSI
|
0.048x |
|
Guanghui Logistics Co Ltd
SHG:600603
|
0.005x |
|
Hangzhou Weiguang Electronic Co Ltd
SHE:002801
|
0.045x |
|
Simply Good Foods Co
NASDAQ:SMPL
|
0.031x |
|
Wuhan Zhongyuan Huadian Sci Tech
SHE:300018
|
0.071x |
Annual Cash Flow Conversion Efficiency for Odyssey Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of Odyssey Therapeutics, Inc. Common Stock from 2022 to 2025. Also see ODTX total assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-488.28 Million | $-129.47 Million | 0.265x | -13.66% |
| 2024-12-31 | $-382.53 Million | $-117.47 Million | 0.307x | -28.43% |
| 2023-12-31 | $-262.71 Million | $-112.73 Million | 0.429x | -37.85% |
| 2022-12-31 | $-144.62 Million | $-99.84 Million | 0.690x | -- |
About Odyssey Therapeutics, Inc. Common Stock
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated … Read more